![]() | Augustus John RushShow email addressDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA | Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Augustus John Rush:Expert Impact
Concepts for whichAugustus John Rushhas direct influence:Major depressive disorder,Bipolar disorder,Depressive disorder,Major depression,Major depressive,Cognitive therapy,Depressive symptoms,Depressive symptomatology.
Augustus John Rush:KOL impact
Concepts related to the work of other authors for whichfor which Augustus John Rush has influence:Bipolar disorder,Depressive symptoms,Major depression,Mental health,Electroconvulsive therapy,Suicidal ideation,Depressed patients.
KOL Resume for Augustus John Rush
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA Duke-National University of Singapore, Singapore |
2021 | Department of Psychiatry, Texas Tech University Health Sciences Center, Permian Basin Campus, Odessa, TX, USA Professor Emeritus, Duke-National University of Singapore, Singapore Corresponding author: A. John Rush, MD, Curbstone Consultant LLC, 7 Avenida Vista Grande #112, Santa Fe, NM 87508 |
2020 | National University of Singapore, Singapore Department of Orthopedics, University of Miami / Jackson Memorial Hospital, Miami, FL, USA Texas Tech University, Lubbock, Texas, United States of America |
2019 | Duke‐National University of Singapore Medical School, Singapore, Singapore Department of Psychiatry, Duke Medical School, Durham, NC, USA Adjunct Clinical Professor, Texas Tech University-Health Sciences Center, Permian Basin, Texas (Dr Rush) |
Concept | World rank |
---|---|
subtype groups | #1 |
nonsingle | #1 |
depression practice | #1 |
remission study exit | #1 |
suicide ideation increase | #1 |
presence painful symptoms | #1 |
early responders responders | #1 |
sleep polysomnography children | #1 |
late responders vns | #1 |
depression hrsd17 | #1 |
continuation treatment relapse | #1 |
c8 95cis | #1 |
reduced rapid | #1 |
qids c₁₆ qidssr₁₆ | #1 |
patients idssr30 | #1 |
clinically predictors | #1 |
depression ongoing treatment | #1 |
weeklymean | #1 |
miniqlesq hrsd6 | #1 |
desipramine phenelzine | #1 |
vqidsc5 | #1 |
wsas baseline | #1 |
antenatal dysphoria | #1 |
remission treatment steps | #1 |
atypical features citalopram | #1 |
response qidssr16 | #1 |
groups wsas | #1 |
dimensionality depression scales | #1 |
united states citalopram | #1 |
28 inpatients | #1 |
diurnal mood variation | #1 |
accessing medical records | #1 |
selfoutlook | #1 |
release bias | #1 |
sertraline maintenance | #1 |
qidssr16 cutoff scores | #1 |
ect remission rates | #1 |
ketoconazole bipolar patients | #1 |
total scores idssr30 | #1 |
bipolar disorder module | #1 |
menopause status postmenopausal | #1 |
cbasp combination therapy | #1 |
gaba levels placebo | #1 |
patients sreml | #1 |
madrs adult outpatients | #1 |
intolerance citalopram | #1 |
thyroid failure outpatients | #1 |
major depression outcomes | #1 |
multiple types cmt | #1 |
single patients scores | #1 |
Sign-in to see all concepts, it's free! | |
Prominent publications by Augustus John Rush
CONTEXT: Children of depressed parents have high rates of anxiety, disruptive, and depressive disorders that begin early, often continue into adulthood, and are impairing.
OBJECTIVE: To determine whether effective treatment with medication of women with major depression is associated with reduction of symptoms and diagnoses in their children.
DESIGN: Assessments of children whose depressed mothers were being treated with medication as part of the multicenter Sequenced Treatment ...
Known for Children Mothers | Maternal Depression | Child Psychopathology | 3 Months | Treatment Depressed |
BACKGROUND: The present study provides additional data on the psychometric properties of the 30-item Inventory of Depressive Symptomatology (IDS) and of the recently developed Quick Inventory of Depressive Symptomatology (QIDS), a brief 16-item symptom severity rating scale that was derived from the longer form. Both the IDS and QIDS are available in matched clinician-rated (IDS-C30; QIDS-C16) and self-report (IDS-SR30; QIDS-SR16) formats.
METHOD: The patient samples included 544 ...
Known for Depressive Symptomatology | Clinician Rating | Patients Mdd | Mood Disorders | Psychometric Evaluation |
The Epidemiology of Major Depressive Disorder: Results From the National Comorbidity Survey Replication (NCS-R)
[ PUBLICATION ]
CONTEXT: Uncertainties exist about prevalence and correlates of major depressive disorder (MDD).
OBJECTIVE: To present nationally representative data on prevalence and correlates of MDD by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, and on study patterns and correlates of treatment and treatment adequacy from the recently completed National Comorbidity Survey Replication (NCS-R).
DESIGN: Face-to-face household survey conducted from February ...
Known for Major Depressive Disorder | Mdd Treatment | Prevalence Correlates | Comorbidity Survey | Role Impairment |
Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder
[ PUBLICATION ]
OBJECTIVE: To develop effect sizes for 3 mood stabilizers--lithium, divalproex sodium, and carbamazepine--for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years.
METHOD: Forty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy ...
Known for Divalproex Sodium | Bipolar Disorder | Lithium Carbamazepine | Treatment Children | Mixed Manic Episode |
Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents
[ PUBLICATION ]
OBJECTIVE: The authors compared fluoxetine and placebo in continuation treatment to prevent relapse of major depressive disorder in children and adolescents.
METHOD: After a detailed evaluation, children and adolescents 7-18 years of age with major depressive disorder were treated openly with fluoxetine. Those who had an adequate response after 12 weeks, as indicated by a Clinical Global Impression improvement score of 1 or 2 and a decrease of at least 50% in Children's Depression Rating ...
Known for Major Depression | Fluoxetine Placebo | Preventing Relapse | Children Adolescents | Continuation Treatment |
Axis I Psychiatric Comorbidity and Its Relationship to Historical Illness Variables in 288 Patients With Bipolar Disorder
[ PUBLICATION ]
OBJECTIVE: Bipolar disorder often co-occurs with other axis I disorders, but little is known about the relationships between the clinical features of bipolar illness and these comorbid conditions. Therefore, the authors assessed comorbid lifetime and current axis I disorders in 288 patients with bipolar disorder and the relationships of these comorbid disorders to selected demographic and historical illness variables.
METHOD: They evaluated 288 outpatients with bipolar I or II disorder, ...
Known for Bipolar Disorder | Comorbidity Patients | Current Axis | Earlier Age | Illness Onset |
Sleep polysomnography as a predictor of recurrence in children and adolescents with major depressive disorder
[ PUBLICATION ]
Adults with major depressive disorder (MDD) demonstrate certain sleep polysomnographic abnormalities, including sleep continuity disturbances, reduced slow-wave sleep, shortened rapid eye movement (REM) latency, and increased REM density. Findings of sleep EEG studies in depressed children and adolescents have yielded conflicting results, possibly because of methodological variations across the studies. Generally, however, studies have demonstrated that depressed children and adolescents ...
Known for Major Depressive Disorder | Children Adolescents | Sleep Polysomnography | Episode Mdd | Follow Studies |
Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder
[ PUBLICATION ]
BACKGROUND: Sleep disturbances are common in major depressive disorder. In previous open-label trials, nefazodone improved sleep continuity and increased rapid eye movement (REM) sleep, while not affecting stage 3/4 sleep or REM latency: in contrast, fluoxetine suppressed REM sleep. This study compared the objective and subjective effects of nefazodone and fluoxetine on sleep.
METHODS: This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, ...
Known for Nefazodone Fluoxetine | Major Depressive Disorder | Rem Sleep | Depressive Symptoms | Uptake Inhibitors |
OBJECTIVE: To compare and describe the weight loss outcomes from gastric bypass and gastric band so as to define the variation of excess weight loss (EWL) among individual patients, the time to onset of effect, and the durability of weight loss in severely obese adults.
SUMMARY BACKGROUND DATA: Gastric bypass and gastric band are the most common operations for obesity performed in the United States, but few reports have compared these 2 procedures.
METHODS: Patients (N = 1733, aged 18-65 ...
Known for Gastric Bypass | Weight Loss | 2 Years | Obesity Surgery | Ewl 6 |
OBJECTIVE: The purpose of this study was to determine whether adjunctive use of a psychostimulant (mixed amphetamine salts) was safe and efficacious for treatment of symptoms of attention deficit hyperactivity disorder (ADHD) in pediatric outpatients with bipolar I or bipolar II disorder and concurrent ADHD whose manic symptoms had been stabilized through treatment with divalproex sodium.
METHOD: An 8-week open-label trial of divalproex sodium to control manic symptoms and to discern the ...
Known for Bipolar Disorder | Mixed Amphetamine Salts | Comorbid Adhd | Manic Symptoms | Mood Stabilization |
IMPORTANCE: Current guidelines recommend treating severe depression with pharmacotherapy. Randomized clinical trials as well as traditional meta-analyses have considerable limitations in testing for moderators of treatment outcomes.
OBJECTIVES: To conduct a systematic literature search, collect primary data from trials, and analyze baseline depression severity as a moderator of treatment outcomes between cognitive behavioral therapy (CBT) and antidepressant medication (ADM).
DATA ...
Known for Depression Severity | Cognitive Behavioral Therapy | Cbt Adm | Patient Data | Hamd Bdi |
BACKGROUND: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain.
METHODS: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item ...
Known for Nefazodone Psychotherapy | Cognitive Behavioral | Chronic Depression | Response Remission | 12 Weeks |